PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF HUMAN HYPOCHOLINERGIC DISORDERS
The present invention proposes an improvement of the efficacy of donepezil for the palliative treatment of Dementia of the Alzheimer-type by counteracting its peripheral dose-limiting adverse effects with a selective peripheral M1-antagonist such as, preferably, pirenzepine, thus enabling a safe inc...
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Patent |
Sprache: | eng ; fre ; ger |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The present invention proposes an improvement of the efficacy of donepezil for the palliative treatment of Dementia of the Alzheimer-type by counteracting its peripheral dose-limiting adverse effects with a selective peripheral M1-antagonist such as, preferably, pirenzepine, thus enabling a safe increase of the donepezil dose and consequently improved efficacy. In particular, an aim of the present invention is at least the slowing of the progression of dementia in patients suffering from a Hypocholinergic Disorder such as Alzheimer disease, Lewy body disease, Parkinson's Disease or Mild Cognitive Impairment by a safe administration of donepezil increased doses in combination with pirenzepine, as a peripheral antimuscarinic agent. This combination allows said safe treatment where other donepezil combinations failed. |
---|